{"ticker": {"uuid": "69037a6d-0b2d-426a-9e9a-1fe02c74f531", "symbol": "GMAB", "name": "Genmab A/S", "exchange": "VIE", "country": "AT", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNX0xsSi1xdkQzRkFEcERYR1B3X0x5SThtSEhZUHhNOGZGOTFFV2U1UWlQNVdXUFA1UVhSS3k3OWtaSG51S0cxNzN0bWZtZldDM0pFX3diYTdlMWdtSGJlVEFwYjVBdUY5UHE5SE9XNXZZRTJQVW5OUndjVUdDdEdrVE9SMDZoMWZPTW05S2czSUR5REJfc2lGZnRHZjdOOWJxdWFxSUloMU9WQ1laZFhHUGFnLWtUZw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T11:28:42+00:00", "published_display": "15 Jul 2026 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (Nasdaq: GMAB) reports USD 4,207 million Q2 DARZALEX sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcFVqSWZyYktvYkotSVo1TnBtUG94X2FiNTFhYzBMMGU4MDFGanpKT2N2VEp0ZnVKRDBnUmUzMUxFZ2ZzRy1SaFR4UzJlOWxxQk5yZ1lncENXWDQ2N1ludG1QLVJ5MXhMYVN2MktjOHhocmxhRmt1c0Jja00wbkpLZF9PbUtrSlMwSEFibG5EOWpia2RlZXN4d3dfWTJ3TGNnMDFqMjk5UGtSQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T11:22:42+00:00", "published_display": "15 Jul 2026 11:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (GMAB) Stock Analysis: Unlocking A 26.68% Upside With Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNT3JiNVJ4X3lyYnlIVXNFWUZ5MVBQb0g5cGtKbGZzWjN4NlBkN3VRa0hnb1B3UVdTV2NHSGZKcVJaaVBRM2NFRFpXdXU4QzdZeGZMQ3dsRzUyalBNTjFTRUxBa3ZGVFl4VzRtNUs3UUVESzdMOTZTNzBQaDc5VlhnVDRkRHhjazFTR2xfX1F6eEdDcld3ZUJHaE5rQXZ1RWk2TnJCeXpmc3Z5V3VTY0MxZmY3SlpiRnc1OU1ZRjFTa2R3c09MdjZBNQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:19:12+00:00", "published_display": "13 Jul 2026 09:19", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQNFpiZWVhZ0ZDNnlrS1lKcGl5R3hGMDNMMFBHcGY4UEJTd0tQUWpBTUhJN2J5V3M3MG5zaGR1LVJxQTU3a2JuclpJc0NvOGJIbmVsNEgydlVRLVhmcGE0dHFnQmkzWldrZVp1U3FWZmJEeHg2QlpfZm1mM3RyVWU4T212TmdWblliR2lkVHQzSzBJQURySzc1NldEZ05PckxK?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab rebounds on a European Commission decision", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQSnZWblVHYUZMV0x0elVyZkI5aDd3S1ZhNmhYby1DZnNuNjN1Yy1aSklRRDJrM1NJcHJmWVBLZVd5d2NGLXlKczN2MGlfMHViY0NIUjlEZGhEcEVxX3BGUDlIdmhuc2FkU0xFdlVPUWtnczF4Q0xCeGYySlJ1SUw3b1hWNlpLNkZMenFyNHNLT0VPZ0liNmNXclJEbzdBOUtOX3JKNg?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-07T07:52:22+00:00", "published_display": "07 Jul 2026 07:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Europe approves Genmab's TEPKINLY combo for relapsed follicular lymphoma", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNQnU3NnNXVm9lM3FhOFF2MUNidnZKaEZQeFBLWUZIQXRvWFp2YnJUNDNMaDgzSDJPb1ljWWw3UDd1a0xjQko4TnRITkNfZTI3dHZ6N2gybGs2SUJIdzFZZ1N4UkN1SlI2Z2JVQVBmd3N4dklJcFdoVEdxWVd6Tms0LUtlRURFY0ZyVTJnM2JuNTRqYklOQS1mYURLUnViV042S202SlBHQkZJRzJnWTd0TEpn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab lymphoma trial cuts progression risk 60% in phase 3 study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNckZUcExPdF92eDZNTC1FamFmaUhwUUFiYTE0OGVxN1FoVFFUMHo4ZEJGS05ZNzFDaTB5RkxnT05lZVplV3BjVWtKVDdHZ3kyMEVNdjJVWWVSSVFhellVR19xRy1TZkd4Q0Q2aktLMThLRGpEYUtjdjdkYkhhUTR4WTRqSTBSempudWxiaWVpbGgzY3BUb3hCYXJ3VE92Ym9ZcDRqWmdQZll1SUhralprczkzeGwwVi1w?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab: Financing weighs now, pipeline pays later", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOZlByeUZOdllhNE1mTi0xZ29tcDFzSDBsNU9oUWhnX3dMdEdnYmpPakdmTHJqUkhLbGVxRGlvM1NWaVQ5VWQzTXY5aFpTeC05dFZNeHA5dVg5cTJXWE5xZ1Z1c0M4bE1IY3hEM2pWSFctRlBYU1gxNGNTRndRajM2a3kyQmQ0Tl9YTGNJYTRmZnlqeVF3dUtiWGVVcWdONzNiN2c?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Assigns Buy Rating to Genmab (GMAB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNM1VNTnRZb3pWZjUya0VoS2RBdWs1X2VORTgxWlRDTkh1QTdxQWhGOThweHhIaE1lcEdUanFhb3YtbXdnb1ZHLW5ObHQ0bUVUYjZzWnV6VDdNR0x4VWE5VUhQdi1EbF9jZEtuSXFLWHhhS0dOUkpJemlXTE9naFYyWVpRXzBESXNuRE8tcE5uUUR3VlI2d0RQUEhaUWZ6Zw?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab\u2019s epcoritamab phase 3 lymphoma results set for ASCO and EHA 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSEdhWGhwYXZIaDRubmctcF9WdTNQX3FfMjlULWJySy1ZLW9VWVNYX0JsWkRLdm5LUHlROGZ5U3llRktocVhPZ2tKbHpLal9rNFBaZFhHTEh2c29qVXNXX2RsaUIzNkw2R0pydkFGcWxZS1NMZndYOFVuQ2dNX085Y1VKbi1reG9ySEVISGJzMXo2TVVNQTZmMVh0UFZrcXVMQUdNNERVYnF1NE1uUUJCSHhCUUE3WVdBVUFGTw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNLWV6MExvM1NSUEJ5eE5CaU1tZERrby1IaFFnN2IxR2xpWFo0NjVZczY1VUkyT3g4NWI5TU8tMm5iaGVQdU90eEVmMXhoRzhzQnBBd3hSTUdHaTJRSFo3REJHLUpLWjRPSVRPYVNlOFl5SGc5d0VCM1Q2b3JmZ29DOGFla0RManlPdFR4bEVLRnAxbEljNThRdU90aDczdw?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi\u2011Year Share Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOUjhiOXlYYkF3RHFBUXVPY2tTbzQ4VlJCandIeDhHMmJrZzl5YWIyVDA2UmRXTTFSLWFlMnNrRnFlcHROUVdZUnVsVHBaSTljOEphVFM2bkhtZWJTbk1fekc2OWVYZnRZLU9VZ3FFT1ZrOVhsNlZxdzFrei1HTWxtdk1lazVfN0xzY0x1Z2ZidWFaNkk4UUdUYUlhNA?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (GMAB) stock falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNaUh6a2RmMnNjNFB2VnI3MTNTTGlfWTl6WExfRFhzRHRJOHJhdzhYbkNld0NaLUFpekFfemdPbmdSM1pCaG5hcEZTaGQ2WEhZWGJqSXZReWh0djNMZDlrUjZQSWZVbHJaRERwQ0dpRkFBclBZZ29HT1Fvc2VueFFvMG8wR2hMUEZKeDIzZlVaWEhpQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Rated Outperform on Oncology Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZmpxd1NpbTVHX3pZc2VyVjVpWVliSUNWYmFLbmZObkk2ejdmc0k1ME9ZdEwwZjFhVkNIblYyMTJBdWF5NlZfeVVueldkbU9Ydi1EUERPYnVsVUp0cm0wRmZqcXdwOXpZV2tyVXFndWppZHg4a21GN0JQQW9RNzVlUnJpMndkZHJreXNOUEFxZ2VCaHE1ZkhMTDJFT083X1FDMjdneDVvRnBRZw?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Upgrades Genmab to Buy From Neutral, Adjusts Price Target to $30.50 From $24.50", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPY1gtdWpNLUpvNDV3eVhVejU4V0JzOW5lQl85UFUwQXQ5NnkzS2pjNmYtbGxxUjQwU3RtMnZ0VVV0S25YWlN1NDBFVW5RdTVwc2EzSDVaMzMtQ3NFS1lmV1JRYkJOOHJQWF9Oc2drLWJSaGRPdlNFYkZCbDN4dDBtUGcyVFVQeGFJZ1QwTllpRmZ1RWhVdE83NEJqZlJQRXZPRWJUcVBldzdYbzFtajBvNnI5S3NHZHpvZDVybjFOdW5ERVlkQjV5Q2RxWEVXbnZqQldsWFZRVFVvUjA?oc=5", "source_name": "marketscreener.com", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Genmab\u2019s (CPSE:GMAB) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQOXhrV3ZBMURTTVVITTdQZ1Z3YzYxUE40alV4bEJ1VjN4N19rbTdmdkN1NWVWdThHeXFiOE5WNnotWEFVcE1GVTBIS1dOdzZPNVFWdUxmLUdqM3VCbHdWa09hWGJ5R0JUek9OQnRDZFBISnNfU3NrblpYTGtuTGZKcFFtcXpKaldOT1VMbE9aNHR0WnI3WmVxYjhWd1g?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNQk9kRTlPdmQtaF9uUVhlTXhHSjIxd1JJZ2toUEJTUXQ0c3k4N3dqNlNva0VvREJYYWVwaHVNQTBHUm5zbVd6MGZ6OHQya1JPRk5QZ0JvUnhGU21OR1hZNmxQR0FOTDRPTElWUnZ3aThqYXhBdU1aa1ZodVgxWGhMTDRoemtoeFd6TFdnd2hLUi1nN2FFUlpBSkg1ZFVzNVJl?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNdnJwT19rRjVEN3JfUnBWTlJ1bUZZUG1tRWJBX21KYWtDcmJWWkw5MnVOaWgwR0JKeXQwUkU4cU9yOG54R0NiMnoxc1czbjV6eXZyOVV5eHMxb1dtbjExbmUtNXp1UHFocVUwZjFrRHhHYlVDb2xfd3ZNYnVIbGlVczM5aFh6bF82WmJ5eWlpVHdqWHJfa3Z1Vnp2ZDRmRHBaM2RQZ1NNOWRRUzE5QWh3SW8zcFExUDZvRkVKZVRSdVBsZw?oc=5", "source_name": "ChartMill", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Genmab (CPSE:GMAB) Narrative Is Shifting As 2026 Catalyst Risks Build", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNOTZnQTlGYnljWm1NT25BN2tRQVl4dzNqZWIyZU5mOG04MHE1WWJCZTVad2RIaFdXS3l6QUJuTTg0ZjBNWjh0SUNfeU1ZTUtubWtyYWZFZnozWWZjZWxDaWtmQXNYYXdoVWt3UjhIbURYM19CS21FUkZLUl95Tmt1TlljR0dpLW5S?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNcm5lb2IwQUhyVEFlYmFRaG40U0lzUzdOVU5HVzd3ZDFiQk96RHdLWUxVTXcwUGt0MUhCZkloUjQ4akwwUG5WMzZZSGN2N252ajZyMmgyTGp0OExvYlZJby1UQUtFSlhYRUVkQ210YmZkNE8yVXBnQ0RVYnRFMXhMT09R?oc=5", "source_name": "Market source", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB)\u2019s Future Potential Underappreciated by Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOWWlrWWpHU1pOaVU2TlAzaUhtQ19uc3kzU0htYzJyYUJGeTJCRlI3RHRqT21VYzUzYVYxVGhvQVFaWDhtVmtzQktDVUNCS3pjUGxYeFBfbkU4eG1zRnd2X1RKRVhmbTREeFI5NTZ2azFvdW92LTE2dmt1WUpOV3NDRWlNc2M1bWhFYUpwcndmWVhGeWxWOFE?oc=5", "source_name": "Market source", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S: Financial Data Forecasts Estimates and Expectations | GMAB | DK0010272202", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTFA0Q2N4UVhqN29Db3c1M01sdVVVd3FoV2sxNm55a0FZU213bldMM2doYTNQNU1pc05QZm55WkotNkFoNXgtaVNIT0hLUWZiYTJZTmFzcmk4NlBNaU5DQ3dkUUdRUnl6czdqekZfaENBY0RvN0RXSXZDMDVKY28?oc=5", "source_name": "marketscreener.com", "published_at": "2023-06-22T11:30:12+00:00", "published_display": "22 Jun 2023 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S: Target Price Consensus and Analysts Recommendations | GMAB | DK0010272202", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5leFpSWk1BV0VGcXVhY2lNY0tuSnB2Wm1ScVZiLUVpTWkxdDBQREFWZlMtajI4MXRkWHctY2J4cElOMnZfa1dEX05OUmRoaFMzQzF1U0ZuNGlMUm9OcDB0ZEhTSHplUm9zNW9fUGVPVGlyeXVmQkpDV3NTQnNsZw?oc=5", "source_name": "marketscreener.com", "published_at": "2020-08-24T23:12:48+00:00", "published_display": "24 Aug 2020 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNX0xsSi1xdkQzRkFEcERYR1B3X0x5SThtSEhZUHhNOGZGOTFFV2U1UWlQNVdXUFA1UVhSS3k3OWtaSG51S0cxNzN0bWZtZldDM0pFX3diYTdlMWdtSGJlVEFwYjVBdUY5UHE5SE9XNXZZRTJQVW5OUndjVUdDdEdrVE9SMDZoMWZPTW05S2czSUR5REJfc2lGZnRHZjdOOWJxdWFxSUloMU9WQ1laZFhHUGFnLWtUZw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T11:28:42+00:00", "published_display": "15 Jul 2026 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (Nasdaq: GMAB) reports USD 4,207 million Q2 DARZALEX sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcFVqSWZyYktvYkotSVo1TnBtUG94X2FiNTFhYzBMMGU4MDFGanpKT2N2VEp0ZnVKRDBnUmUzMUxFZ2ZzRy1SaFR4UzJlOWxxQk5yZ1lncENXWDQ2N1ludG1QLVJ5MXhMYVN2MktjOHhocmxhRmt1c0Jja00wbkpLZF9PbUtrSlMwSEFibG5EOWpia2RlZXN4d3dfWTJ3TGNnMDFqMjk5UGtSQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T11:22:42+00:00", "published_display": "15 Jul 2026 11:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (GMAB) Stock Analysis: Unlocking A 26.68% Upside With Strong Buy Ratings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNT3JiNVJ4X3lyYnlIVXNFWUZ5MVBQb0g5cGtKbGZzWjN4NlBkN3VRa0hnb1B3UVdTV2NHSGZKcVJaaVBRM2NFRFpXdXU4QzdZeGZMQ3dsRzUyalBNTjFTRUxBa3ZGVFl4VzRtNUs3UUVESzdMOTZTNzBQaDc5VlhnVDRkRHhjazFTR2xfX1F6eEdDcld3ZUJHaE5rQXZ1RWk2TnJCeXpmc3Z5V3VTY0MxZmY3SlpiRnc1OU1ZRjFTa2R3c09MdjZBNQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:19:12+00:00", "published_display": "13 Jul 2026 09:19", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQNFpiZWVhZ0ZDNnlrS1lKcGl5R3hGMDNMMFBHcGY4UEJTd0tQUWpBTUhJN2J5V3M3MG5zaGR1LVJxQTU3a2JuclpJc0NvOGJIbmVsNEgydlVRLVhmcGE0dHFnQmkzWldrZVp1U3FWZmJEeHg2QlpfZm1mM3RyVWU4T212TmdWblliR2lkVHQzSzBJQURySzc1NldEZ05PckxK?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab rebounds on a European Commission decision", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQSnZWblVHYUZMV0x0elVyZkI5aDd3S1ZhNmhYby1DZnNuNjN1Yy1aSklRRDJrM1NJcHJmWVBLZVd5d2NGLXlKczN2MGlfMHViY0NIUjlEZGhEcEVxX3BGUDlIdmhuc2FkU0xFdlVPUWtnczF4Q0xCeGYySlJ1SUw3b1hWNlpLNkZMenFyNHNLT0VPZ0liNmNXclJEbzdBOUtOX3JKNg?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-07T07:52:22+00:00", "published_display": "07 Jul 2026 07:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Europe approves Genmab's TEPKINLY combo for relapsed follicular lymphoma", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNQnU3NnNXVm9lM3FhOFF2MUNidnZKaEZQeFBLWUZIQXRvWFp2YnJUNDNMaDgzSDJPb1ljWWw3UDd1a0xjQko4TnRITkNfZTI3dHZ6N2gybGs2SUJIdzFZZ1N4UkN1SlI2Z2JVQVBmd3N4dklJcFdoVEdxWVd6Tms0LUtlRURFY0ZyVTJnM2JuNTRqYklOQS1mYURLUnViV042S202SlBHQkZJRzJnWTd0TEpn?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab lymphoma trial cuts progression risk 60% in phase 3 study", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNckZUcExPdF92eDZNTC1FamFmaUhwUUFiYTE0OGVxN1FoVFFUMHo4ZEJGS05ZNzFDaTB5RkxnT05lZVplV3BjVWtKVDdHZ3kyMEVNdjJVWWVSSVFhellVR19xRy1TZkd4Q0Q2aktLMThLRGpEYUtjdjdkYkhhUTR4WTRqSTBSempudWxiaWVpbGgzY3BUb3hCYXJ3VE92Ym9ZcDRqWmdQZll1SUhralprczkzeGwwVi1w?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab: Financing weighs now, pipeline pays later", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOZlByeUZOdllhNE1mTi0xZ29tcDFzSDBsNU9oUWhnX3dMdEdnYmpPakdmTHJqUkhLbGVxRGlvM1NWaVQ5VWQzTXY5aFpTeC05dFZNeHA5dVg5cTJXWE5xZ1Z1c0M4bE1IY3hEM2pWSFctRlBYU1gxNGNTRndRajM2a3kyQmQ0Tl9YTGNJYTRmZnlqeVF3dUtiWGVVcWdONzNiN2c?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Assigns Buy Rating to Genmab (GMAB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNM1VNTnRZb3pWZjUya0VoS2RBdWs1X2VORTgxWlRDTkh1QTdxQWhGOThweHhIaE1lcEdUanFhb3YtbXdnb1ZHLW5ObHQ0bUVUYjZzWnV6VDdNR0x4VWE5VUhQdi1EbF9jZEtuSXFLWHhhS0dOUkpJemlXTE9naFYyWVpRXzBESXNuRE8tcE5uUUR3VlI2d0RQUEhaUWZ6Zw?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab\u2019s epcoritamab phase 3 lymphoma results set for ASCO and EHA 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPSEdhWGhwYXZIaDRubmctcF9WdTNQX3FfMjlULWJySy1ZLW9VWVNYX0JsWkRLdm5LUHlROGZ5U3llRktocVhPZ2tKbHpLal9rNFBaZFhHTEh2c29qVXNXX2RsaUIzNkw2R0pydkFGcWxZS1NMZndYOFVuQ2dNX085Y1VKbi1reG9ySEVISGJzMXo2TVVNQTZmMVh0UFZrcXVMQUdNNERVYnF1NE1uUUJCSHhCUUE3WVdBVUFGTw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNLWV6MExvM1NSUEJ5eE5CaU1tZERrby1IaFFnN2IxR2xpWFo0NjVZczY1VUkyT3g4NWI5TU8tMm5iaGVQdU90eEVmMXhoRzhzQnBBd3hSTUdHaTJRSFo3REJHLUpLWjRPSVRPYVNlOFl5SGc5d0VCM1Q2b3JmZ29DOGFla0RManlPdFR4bEVLRnAxbEljNThRdU90aDczdw?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi\u2011Year Share Performance", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOUjhiOXlYYkF3RHFBUXVPY2tTbzQ4VlJCandIeDhHMmJrZzl5YWIyVDA2UmRXTTFSLWFlMnNrRnFlcHROUVdZUnVsVHBaSTljOEphVFM2bkhtZWJTbk1fekc2OWVYZnRZLU9VZ3FFT1ZrOVhsNlZxdzFrei1HTWxtdk1lazVfN0xzY0x1Z2ZidWFaNkk4UUdUYUlhNA?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S (GMAB) stock falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNaUh6a2RmMnNjNFB2VnI3MTNTTGlfWTl6WExfRFhzRHRJOHJhdzhYbkNld0NaLUFpekFfemdPbmdSM1pCaG5hcEZTaGQ2WEhZWGJqSXZReWh0djNMZDlrUjZQSWZVbHJaRERwQ0dpRkFBclBZZ29HT1Fvc2VueFFvMG8wR2hMUEZKeDIzZlVaWEhpQQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Rated Outperform on Oncology Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZmpxd1NpbTVHX3pZc2VyVjVpWVliSUNWYmFLbmZObkk2ejdmc0k1ME9ZdEwwZjFhVkNIblYyMTJBdWF5NlZfeVVueldkbU9Ydi1EUERPYnVsVUp0cm0wRmZqcXdwOXpZV2tyVXFndWppZHg4a21GN0JQQW9RNzVlUnJpMndkZHJreXNOUEFxZ2VCaHE1ZkhMTDJFT083X1FDMjdneDVvRnBRZw?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Upgrades Genmab to Buy From Neutral, Adjusts Price Target to $30.50 From $24.50", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxPY1gtdWpNLUpvNDV3eVhVejU4V0JzOW5lQl85UFUwQXQ5NnkzS2pjNmYtbGxxUjQwU3RtMnZ0VVV0S25YWlN1NDBFVW5RdTVwc2EzSDVaMzMtQ3NFS1lmV1JRYkJOOHJQWF9Oc2drLWJSaGRPdlNFYkZCbDN4dDBtUGcyVFVQeGFJZ1QwTllpRmZ1RWhVdE83NEJqZlJQRXZPRWJUcVBldzdYbzFtajBvNnI5S3NHZHpvZDVybjFOdW5ERVlkQjV5Q2RxWEVXbnZqQldsWFZRVFVvUjA?oc=5", "source_name": "marketscreener.com", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Genmab\u2019s (CPSE:GMAB) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQOXhrV3ZBMURTTVVITTdQZ1Z3YzYxUE40alV4bEJ1VjN4N19rbTdmdkN1NWVWdThHeXFiOE5WNnotWEFVcE1GVTBIS1dOdzZPNVFWdUxmLUdqM3VCbHdWa09hWGJ5R0JUek9OQnRDZFBISnNfU3NrblpYTGtuTGZKcFFtcXpKaldOT1VMbE9aNHR0WnI3WmVxYjhWd1g?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Fuels Confidence Based on Upcoming Epkinly and Petosemtamab Readouts", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNQk9kRTlPdmQtaF9uUVhlTXhHSjIxd1JJZ2toUEJTUXQ0c3k4N3dqNlNva0VvREJYYWVwaHVNQTBHUm5zbVd6MGZ6OHQya1JPRk5QZ0JvUnhGU21OR1hZNmxQR0FOTDRPTElWUnZ3aThqYXhBdU1aa1ZodVgxWGhMTDRoemtoeFd6TFdnd2hLUi1nN2FFUlpBSkg1ZFVzNVJl?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNdnJwT19rRjVEN3JfUnBWTlJ1bUZZUG1tRWJBX21KYWtDcmJWWkw5MnVOaWgwR0JKeXQwUkU4cU9yOG54R0NiMnoxc1czbjV6eXZyOVV5eHMxb1dtbjExbmUtNXp1UHFocVUwZjFrRHhHYlVDb2xfd3ZNYnVIbGlVczM5aFh6bF82WmJ5eWlpVHdqWHJfa3Z1Vnp2ZDRmRHBaM2RQZ1NNOWRRUzE5QWh3SW8zcFExUDZvRkVKZVRSdVBsZw?oc=5", "source_name": "ChartMill", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Genmab (CPSE:GMAB) Narrative Is Shifting As 2026 Catalyst Risks Build", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNOTZnQTlGYnljWm1NT25BN2tRQVl4dzNqZWIyZU5mOG04MHE1WWJCZTVad2RIaFdXS3l6QUJuTTg0ZjBNWjh0SUNfeU1ZTUtubWtyYWZFZnozWWZjZWxDaWtmQXNYYXdoVWt3UjhIbURYM19CS21FUkZLUl95Tmt1TlljR0dpLW5S?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNcm5lb2IwQUhyVEFlYmFRaG40U0lzUzdOVU5HVzd3ZDFiQk96RHdLWUxVTXcwUGt0MUhCZkloUjQ4akwwUG5WMzZZSGN2N252ajZyMmgyTGp0OExvYlZJby1UQUtFSlhYRUVkQ210YmZkNE8yVXBnQ0RVYnRFMXhMT09R?oc=5", "source_name": "Market source", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab (GMAB)\u2019s Future Potential Underappreciated by Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOWWlrWWpHU1pOaVU2TlAzaUhtQ19uc3kzU0htYzJyYUJGeTJCRlI3RHRqT21VYzUzYVYxVGhvQVFaWDhtVmtzQktDVUNCS3pjUGxYeFBfbkU4eG1zRnd2X1RKRVhmbTREeFI5NTZ2azFvdW92LTE2dmt1WUpOV3NDRWlNc2M1bWhFYUpwcndmWVhGeWxWOFE?oc=5", "source_name": "Market source", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S: Financial Data Forecasts Estimates and Expectations | GMAB | DK0010272202", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTFA0Q2N4UVhqN29Db3c1M01sdVVVd3FoV2sxNm55a0FZU213bldMM2doYTNQNU1pc05QZm55WkotNkFoNXgtaVNIT0hLUWZiYTJZTmFzcmk4NlBNaU5DQ3dkUUdRUnl6czdqekZfaENBY0RvN0RXSXZDMDVKY28?oc=5", "source_name": "marketscreener.com", "published_at": "2023-06-22T11:30:12+00:00", "published_display": "22 Jun 2023 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genmab A/S: Target Price Consensus and Analysts Recommendations | GMAB | DK0010272202", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5leFpSWk1BV0VGcXVhY2lNY0tuSnB2Wm1ScVZiLUVpTWkxdDBQREFWZlMtajI4MXRkWHctY2J4cElOMnZfa1dEX05OUmRoaFMzQzF1U0ZuNGlMUm9OcDB0ZEhTSHplUm9zNW9fUGVPVGlyeXVmQkpDV3NTQnNsZw?oc=5", "source_name": "marketscreener.com", "published_at": "2020-08-24T23:12:48+00:00", "published_display": "24 Aug 2020 23:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 77, "total_relevant": 23, "sentiment_summary": {"positive": 6, "negative": 3, "neutral": 14, "score": 53, "total": 23, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 8.25, "count": 15}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}], "positive_events": 6, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 250.3, "latest_week": "2026-07-10", "one_week_move": 0.1, "four_week_move": 16.1, "twelve_week_move": 2.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.588407, "market_dynamics_buy_signal": false, "relative_strength": -16.417406, "fair_value_gap": 1.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.079, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +16.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 53, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "marketscreener.com", "count": 6}, {"label": "Stock Titan", "count": 4}, {"label": "DirectorsTalk Interviews", "count": 1}, {"label": "Quiver Quantitative", "count": 1}, {"label": "ChartMill", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 23}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 15}, {"label": "Earnings", "count": 4}, {"label": "Analyst action", "count": 4}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "23", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.1% over one week, +16.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Genmab's Darzalex Generates $4.21 Billion in Q2 Net Trade Sales"}], "updated_at": "2026-07-18T09:23:00.460660+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}